论文部分内容阅读
[目的]观察依达拉奉治疗急性脑出血的临床疗效。[方法]将70例急性脑出血者随机分为治疗组和对照组。治疗组在常规治疗基础上给予依达拉奉应用共14 d。对照组给予常规治疗,疗程同依达拉奉组,分别于治疗前及治疗后14 d进行神经功能缺损程度及临床疗效评定。[结果]治疗14 d后,治疗组神经功能缺损程度评分明显低于对照组(t=2.75,P﹤0.05);治疗组的有效率显著高于对照组(χ2=4.16,P﹤0.05)。[结论依达拉奉治疗急性脑出血安全有效。
[Objective] To observe the clinical efficacy of edaravone in the treatment of acute cerebral hemorrhage. [Methods] Seventy patients with acute cerebral hemorrhage were randomly divided into treatment group and control group. The treatment group was given edaravone on the basis of routine treatment for a total of 14 days. The control group was given routine treatment. The course of treatment was the same as that of edaravone group. The degree of neurological deficits and clinical efficacy were evaluated before treatment and 14 days after treatment. [Result] After 14 days of treatment, the score of neurological deficit in the treatment group was significantly lower than that in the control group (t = 2.75, P <0.05). The effective rate of the treatment group was significantly higher than that of the control group (χ2 = 4.16, P <0.05). [Conclusion Edaravone is safe and effective in treating acute cerebral hemorrhage.